Glioblastomas: your all-you-need-to-know guide

Written by: Dr Matthew Williams
Published: | Updated: 13/04/2023
Edited by: Conor Lynch

Glioblastomas are aggressive types of tumours that can affect the human brain and spinal cord, which are typically deemed as being highly invasive tumours that typically start in the brain.

 

In our latest article, expert and esteemed clinical oncologist, Dr Matthew Williams, explains in-depth exactly what a glioblastoma tumour is, what the main symptoms are, as well as providing an overview of the various different treatment options available to patients.

What is glioblastoma and what are the main symptoms?

Glioblastoma (GBM) is the most common brain tumour in adults. It is a primary brain tumour (i.e. begins in the brain), and is extremely difficult to treat. Symptoms vary between patients, but typically include headaches, nausea, weakness down one side, as well as problems with memory and speech. However, there are numerous amounts of other causes for these symptoms, and so the diagnosis is normally only initially suspected after a scan of the head.

 

What are the causes of glioblastoma?

As far as we know, there are no common causes for GBM. They are more common in older patients, and slightly more common in men, but apart from some very rare family syndromes, or patients who have had radiation exposure previously, there are no real causal factors. Common lifestyle factors, such as smoking, sleep, or diet, do not seem to increase your chance of developing a glioblastoma tumour.

 

What is the most effective treatment option for glioblastoma?

The most effective treatment is a combination of surgery, radiotherapy and chemotherapy, wherever possible. However, not every tumour is in a place where it can be operated on, and not every patient is well enough to have radiotherapy and chemotherapy. Making these decisions is complex and difficult, and needs a careful assessment of the patient, as well as a thorough discussion of both the pros and cons of the different treatment options available for patients.

 

Is it hereditary? If so, can it be tested for? 

Very rarely is it hereditary. There are some very rare familial syndromes that can increase one’s chances of developing a brain tumour, but these are very rare. For most people, we think that getting diagnosed with a glioblastoma tumour is no more than bad luck.

 

What are the known statistics, and should a patient rely on them? 

There are widely publicised statistics on survival rates in GBM. In general, these are accurate for a group of "standard" patients. However, for patients who are older or younger than the "standard", or where we have additional information on their tumour, these survival predictions can be quite misleading. I would encourage patients to discuss with their oncologist.

 

What should be expected during recovery from glioblastoma?

The aim of treatment is to keep people as well as possible for as long as possible. In some cases, that may be many years, but unfortunately, many patients will succumb to their disease earlier than that.

 

What additional treatments are available for GBM?

Outside of standard treatment, patients should be aware of the option of looking at and considering using other chemotherapy options, such as the use of a second round of radiotherapy (re-irradiation), the use of Avastin (Bevacizumab) as well as Optune.

 

What is Optune?

Optune is one of the few devices that has been shown to improve outcomes in patients with GBM. It is difficult to access, but we have significant experience in helping patients get access to Optune, and currently have the largest patient experience in the UK.

 

What is NGS (Next-Gen Sequencing)?

Next-gen sequencing (NGS) is an attempt to move beyond the standard testing for a few genes to look for mutations that might make the tumour more susceptible to various drug treatments.  Standard NGS is available for all NHS brain tumour patients, but we sometimes also use extended NGS and additional computational tools to better understand and predict tumour behaviour.

 

Dr Matthew Williams is a mightily experienced London-based clinical oncologist who specialises in the diagnosis and treatment of brain tumours. If you are concerned and feel as though you may be suffering from some of the main symptoms of glioblastoma tumours, rest assured that expert medical help and advice is at your disposal. Visit Dr Williams’ Top Doctors profile here to book an appointment with him.

By Dr Matthew Williams
Clinical oncology

Dr Matthew Williams is a leading consultant in clinical oncology and a researcher in the London area with more than 20 years of experience in his field, specialising in neuro-oncology, radiotherapy, chemotherapy, brain and spinal tumours, and IMRT (intensity-modulation radiation therapy). His primary focus is on adult patients with primary and secondary (metastatic) brain tumours. He has a particular interest in developing and applying new treatment approaches, including a second course of radio therapy (re-radiation), and the clinical use of next-generation sequencing to identify options for targeted treatment. 

He completed his undergradute studies in Birmingham, where he then moved to London to become a Senior House Officer at Hammersmith Hospital. After a year in The Gambia running the A&E department, he returned to the UK to complete his clinical oncology training in London. He was awarded PhD funding through Cancer Research UK's (CRUK) Advanced Computation Lab, and holds a PhD in Computer Science from UCL. 

As of 2012, Dr Williams has been a consultant and honorary senior lecturer with Imperial College Healthcare NHS Trust; in 2018 he was promoted to Honorary Senior Fellow at Imperial College.

He leads the Computational Oncology group at Imperial College, where his research focuses on the application of technology and computing to improve cancer care. Dr Williams supervises a range of PhD/MD students with Imperial College researching and studying projects. Recent work includes work on using wearable technology in patients with brain tumour in the BrainWear trial and understanding treatments, as well as outcomes for patients with brain tumours across England in the GlioCova project. He teaches about brain tumours on a European course in oncology and led the London ICR course module on brain tumours for several years.

Dr Matthews' current clinical focus is on the delivery of novel drugs and drug/radiotherapy combinations for patients with primary and metastatic brain tumours. He took part in the first UK expanded access scheme to use Optune widely, and runs the UK's largest Optune clinic. Dr Matthews is one of the few people experienced across all three main stereotactic modalities (Gamma Knife, Cyberknife, and LINAC-based SRS). He also helped found the Advanced Therapies Group at Imperial, which explores the integration of cutting-edge research and clinical practice to deliver novel therapies to patients with brain tumours.

View Profile

Overall assessment of their patients


  • Related procedures
  • Prostate cancer
    Breast cancer
    Bone cancer
    Nervous system malformations
    Brain tumour
    Bone marrow cancers
    Testicular cancer
    Thyroid cancer
    Adrenal glands cancer
    Neuro-oncology
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.